Skip to main content
CL $91.95 -1.05%
CL logo

CL · Colgate Palmolive Co

Track CL — free
$91.95 -0.98 (-1.05%) At close · Aug 14
Market Cap
$73.30B
Shares
797.17M
All earnings calls

Earnings call · FY2025 Q4

Colgate Palmolive Co Q4 FY2025 Earnings Call

Colgate Palmolive Co Q4 FY2025 Earnings Call

Concluded Jan 30, 2026 Audio replay
Jan 30, 2026 53:58 56 turns
Period
FY2025 Q4
Runtime
53:58
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Colgate-Palmolive reported Q4 organic sales growth of 2.2% and full-year organic sales growth of 1.4%, with base business EPS up 4% in Q4 and 3% for the year, while GAAP EPS declined sharply due to skin health goodwill and intangible impairment charges. Management launched its new 2030 strategy and provided 2026 guidance with a wider-than-usual range given category and macro uncertainty.

2030 strategy and building blocks 41 Foreign exchange and pricing 34 M&A and capital allocation 23 Category growth and competitive activity 22 Volatile environment and uncertainty 21 Emerging markets and developed markets divergence 20

Management tone

Positive

Net tone +25 · moderate hedging

Grounding quotes
  • “We delivered organic sales, net sales, gross profit, base business earnings per share, and free cash flow growth in 2025 despite lower-than-expected category growth, higher-than-anticipated raw material inflation, and the impact of higher tariffs.”
  • “I'm confident in our ability to navigate through this uncertain environment. I believe we have the correct long-term strategy, very well-designed 2026 plans, and, of course, the best people and culture so that we can continue to deliver value to all of our stakeholders through achieving our long-term ambitions.”
  • “the market environment remains challenging and volatile. The categories appear to have stabilized, albeit at lower rates than we historically expected, likely between 1.5% and 2.5%.”
  • “The geopolitical environment, including tariffs, is volatile, particularly in Latin America, and the U.S. market remains sluggish. While we think trends will improve, we're not building in a big rebound.”

Forward guidance

3 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $5.23B +5.8% YoY
Gross margin · derived Q4 60.2% -0.1 pp YoY
Net income · derived Q4 -$36.00M -104.9% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Q4 net sales grew 5.8% and organic sales grew 2.2%, with organic sales growth in all four categories in Q4
  • Q4 base business EPS rose 4% to $0.95 and full-year base business EPS rose 3% to $3.69
  • Full-year operating cash flow hit a record $4,198 million; $2.9 billion returned to shareholders via dividends and buybacks
  • Modest Q4 volume growth excluding Prime 100 acquisition and planned private label exit; underlying organic growth exceeded 3% excluding private label
  • Prime 100 acquisition results have consistently exceeded expectations since deal close
  • 2026 organic sales guidance of +1% to +4% represents acceleration versus 2025, supported by a new strategic growth and productivity program

Risks & pressure points

  • Full-year GAAP EPS declined 25% to $2.63 and Q4 GAAP EPS fell 106% to $(0.05) due to skin health goodwill and intangible impairment charges
  • Categories stabilized at historically low rates of 1.5%–2.5% with month-to-month volatility and downward inventory pressure, especially in the U.S.
  • Higher-than-anticipated raw material inflation, higher tariffs, and a sluggish U.S. market pressured results in 2025
  • 2026 guidance range is wider than normal to account for category, geopolitical, and FX uncertainty; no significant U.S. improvement projected in coming quarters
  • Full-year organic sales growth of 1.4% included a 0.7% drag from lower private label pet volume, with planned exit of private label business
  • Foreign exchange has been a headwind in 8 of the past 10 years, and management does not build FX as a tailwind into plans

Key moments

Jump directly to management's words in the synchronized transcript.

“I'll give some brief thoughts on 2025 before heading into why I'm excited for what 2026 could bring despite a very volatile environment as we enter the year. We delivered organic sales, net sales, gross profit, base business earnings per share, and free cash flow growth in 2025 despite lower-than-expected category growth, higher-than-anticipated raw material inflation, and the impact of higher tariffs.” Noel Wallace, CEO
“If categories get worse, we're at the low end of that guidance range, if categories stay where they are, then we're in the middle of that 1% to 4% range. More than likely if category strengthens, we hope to achieve more towards the higher end of that range.” Noel Wallace, CEO

Forward guidance

From the 8-K filed Jan 30, 2026.

Metric Guided
Net sales
Full Year 2026
2% – 6%
Organic sales growth
Full Year 2026
1% – 4%

Guidance from the call

Stated verbally and extracted from the transcript.

Metric Guided
Organic sales growth
2026
1% – 4%

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Buybacks · derived
$406.00M
Dividend / share
$0.53
Full-screen source Call document